-
Pharm Sci Seminar – Herman Sintim
Pharm Sci Seminar – Herman Sintim
Chronic myeloid leukemia, CML, is driven by ABL1 and the introduction of highly effective kinase inhibitors, such as imatinib, has resulted in a 5-year survival rate for CML to approach 90%.